The MacuScope aids in early detection of low macular protective pigment, one of the major risk factors for age-related macular degeneration.

Brilliant Eyecare is now able to provide proactive detection of one of the main risk factors of Age-related Macular Degeneration (AMD), the leading cause of legal blindness in the world today.

With the help of the MacuScope, Brilliant Eyecare can now identify those patients who are at high risk for developing AMD.

AMD currently affects more than 30 million people worldwide. According to the National Eye Institute, this figure could soon approach epidemic proportions, easily doubling in the next 20 to 30 years. It severely affects a person’s central vision making it extremely difficult, if not impossible, to read, drive or perform other activities that require fine, detailed vision.

The MacuScope is the first instrument available today that accurately tracks macular protective pigment density changes in the macula, giving Brilliant Eyecare the ability to place patients into either high-risk or low-risk categories. Brilliant Eyecare recommends that all adults be tested for AMD, especially those over 40 or with a family history of macular degeneration.

“Early detection of disease contributors to Age-related Macular Degeneration is critical to preserving one’s vision,” said Dr. Lloyd Snider, optometric director of MacuChek. “Finding a potential precursor before symptoms start is a major breakthrough in controlling AMD.”

Upon evaluation and detection of those at high risk, Brilliant Eyecare developed a treatment program using ocular supplements to manage the macular protective pigment deficiency. Research has proven that treatment with specific ocular supplements can increase macular protective pigment density within six months.

“A medical device such as the MacuScope is a beneficial addition to Brilliant Eyecare. We are pleased to be able to offer this testing to our patients which could help save their eyesight,” said Dr. Jo Anne Brilliant.